FDA Warns Exosome Maker for Marketing Outside Its IND - MedPage Today
FDA issued a warning letter to an exosome manufacturer for marketing products outside the scope of its Investigational New Drug (IND) application, violating FDA regulations on unapproved drugs and cGMP. This signals increased scrutiny on exosome and cell-based therapies, particularly for companies marketing without proper approvals.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in exosome or cell-based therapies, or any firm marketing products under an IND without approved marketing authorization. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA publicly warned an exosome maker for marketing its product outside the IND, reinforcing that marketing unapproved drugs is illegal and subject to enforcement.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) involved in exosome or cell-based therapies, or any firm marketing products under an IND without approved marketing authorization.
What you must do
Review all marketing and promotional materials for any products under an IND to ensure they are not being marketed as approved or commercially available. Ensure compliance with FDA regulations on investigational drugs.
Deadline
Immediately; ongoing compliance required.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines